跳至主要内容
临床试验/NCT07572552
NCT07572552尚未招募2 期

Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis

Tanta University0 个研究点目标入组 66 人开始时间: 2026年5月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
尚未招募
入组人数
66

研究概览

简要总结

Sepsis is a life-threatening condition defined by organ dysfunction resulting from the body's dysregulated response to an infection (1). It begins with widespread inflammation and cellular damage, which quickly escalates into total circulatory failure and the breakdown of essential organ systems, including the lungs, kidneys, digestive tract, and brain.

This study aims at evaluating the safety and efficacy of fenofibrate versus silymarin for adult patients with sepsis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult age ≥18 years old. Both male and female patients. Patients diagnosed with sepsis regardless of its etiology, according to the definitions of the Surviving Sepsis Campaign (SSC)

排除标准

  • Late septic shock at presentation with multiple organ failure. Serious gastrointestinal disease. Preexisting end-stage liver disease. Preexisting end-stage renal disease. Pregnant and breastfeeding women. History of allergy or intolerance to fenofibrate or silymarin. Patients with malignancies. Uncontrolled hemorrhage. Patients on immunosuppressant or biological therapies.

研究组 & 干预措施

Silymarin group

Experimental

干预措施: Silymarin (Drug)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Aya Ahmed El Attar

Assistant lecturer

Tanta University

相似试验

Clinical Study Evaluating the Efficacy and Safety of... | 临床试验